# Ethical dialogue on Artificial Amniotic sac and Placenta Technology as a treatment option at the limit of viability – results of a Guidance Ethics Workshop

A.H.A. de Boer<sup>1,2</sup>, A. Krom<sup>3</sup>, L. De Proost<sup>3,4</sup>, M. de Vries<sup>5</sup>, M. Hogeveen<sup>2</sup>, M.C. de Vries<sup>3</sup>, R. Geurtzen<sup>2</sup> and E.J.T. Verweij<sup>1</sup>

1. Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, the Netherlands; 2. Department of Neonatology, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, the Netherlands; 3. Department of Medical Ethics and Law, Leiden University Medical Centre, Leiden, the Netherlands; 4. Department of Obstetrics and Gynaecology, Erasmus Medical Centre, Rotterdam, the Netherlands; 5. Institute for Computing and Information Sciences (iCIS), Radboud University Nijmegen, Nijmegen, the Netherlands

# Background

- Extreme prematurity =
   main cause for perinatal
   mortality and morbidity in
   extreme premature birth
- Development Artificial Amniotic sac and Placenta Technology (AAPT) as potential treatment at the limit of viability
- AAPT mimics function of amniotic sac, amniotic fluid and placenta to improve mortality and morbidity
- Currently, animal experiments have yielded promising results, and human trials are imminent.
- Empirical ethical research with relevant stakeholders is an essential component of responsible innovation of AAPT

# Methods – Guidance Ethics Approach

• During a 4h workshop, representatives of patient groups, medical professionals, technologists and policy-makers went through three stages:

#### Phase 1

'Technology in context'

To understand the technology & the context in which it could be used

#### Phase 2

#### 'Dialogue'

Mapping relevant actors whose viewpoint should be considered

Explore potential positive and negative effects of AAPT

Formulate key values at play in those effects

#### Phase 3

#### 'Options for action'

Identifying potential options for action to promote responsible development and use of AAPT:

Ethics by Design | © Ethics in Context | Cethics by User

#### Results\*

### Actors (n=53)

E.g., the child, pregnant person, partner, siblings, healthcare professionals, developers, policy makers, ethicists, researchers, insurance companies, society, the press, charity, researchers, patient organisations.

## Positive (+) & Negative (-) effects

+ Examples (N=14):

Potential for improved outcomes<sup>1</sup>
Less painful procedures
Reduce healthcare costs of long-term
consequences

Proportionality and equality issues

- Examples (n = 40)

A lot of uncertainties regarding the outcome<sup>2</sup>
Effect on the parent-infant bond
Increased complexity of decision-making for parents

# **Values**

Values at play in identified effect

E1: Health, well-being,
quality of life, autonomy,
cost efficiency, safety,
sense of responsibility,
protection, enjoyment,
participation.

E2: Health, solidarity, well-being of child and parent, autonomy, freedom.

# Options for action E2: a lot of uncertainties regarding the outcome

Further development of the technology based on interim results (with frequent evaluation moments).

Set clear boundaries, ensure long-term follow-up, be transparent and honest about data, making the choices clear and understandable

\*The reported results are preliminary and examples of the results we collected during the 4h-workshop

#### Conclusion

For further development and implementation of AAPT, it is essential to continue with (ethical) dialogues and to take into account ethical values, considerations and concerns of relevant stakeholders.



L U L
M C

